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Using andrographolide (AGP) as a template, a series of semisynthetic analogues was 
synthesised for the discovery of new anticancer agent(s) with improved antitumour selectivity 
and potency. SRJ09, a lead compound displayed remarkable activity in the National Cancer 
Institute (NCI) of USA in vitro anticancer screen, particularly against breast and colon 
cancers. The treatment of MCF-7 breast and HCT-116 colon cancer cells with SRJ09 induced 
a G1 phase cell cycle arrest through the down-regulation of CDK-4 expression with 
concomitant up-regulation of p21 expression and without affecting the cyclin D1 expression. 
SRJ09 induced apoptotic cell death in both cells in a p53- and bcl-2-independent manner, 
implicating extrinsic apoptotic pathway. The compound showed impressive in vivo activity 
by delaying HCT-116 tumour xenograft growth in nude mice. Recently, a derivative of 
SRJ09, SRS07 showed vast improvement in the NCI anticancer activity screen compared 
with the parent compound. Additionally, NCI’s in silico COMPARE and SOM analyses 
revealed that the new AGP derivatives have potentially novel molecular target(s). These 
findings although preliminary they are highly suggestive SRS07 have a great potential to be 
developed into a clinical anticancer agent. This research is funded by the Ministry of Science, 
Technology and Innovation of Malaysia (MOSTI) under the IRPA and ScienceFund grant 
schemes. 
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